Oncology News | pharmaphorum

News

Sanofi's immunotherapy Libtayo gets FDA approval in first li...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients.

News

DNA strand and Cancer Cell Oncology Research Concept 3D rendering

Limited access to cancer biomarker testing in Europe, report...

There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology to improve outcomes, according to a new report.

News

MHRA approves Seagen’s oral HER2 drug Tukysa

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission.

News

Nektar lifted by Merck alliance for bempeg, new trial fundin...

Nektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers Squibb’s checkpoint inhibitor Opdivo, but that hasn’

News

Filing beckons as Lynparza hits the mark in adjuvant breast ...

AstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, according to the data monitoring body for the phase 3 OlympiA trial.

News

Merck gets a leg-up for Keytruda in first-line kidney cancer

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the increasingly competitive first-line kidney cancer market.

Sanofi's immunotherapy Libtayo gets FDA approval in first li...

Limited access to cancer biomarker testing in Europe, report...

MHRA approves Seagen’s oral HER2 drug Tukysa

Nektar lifted by Merck alliance for bempeg, new trial fundin...

Filing beckons as Lynparza hits the mark in adjuvant breast ...

Merck gets a leg-up for Keytruda in first-line kidney cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks